Clinical Trial Update: A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations [Phase 2]

View source ↗

Summary

Phase 2 study evaluating patient preference for subcutaneous versus intravenous administration of nivolumab and the nivolumab-relatlimab fixed-dose combination …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• OPDIVO (nivolumab)
• Opdualag (relatlimab and nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-09